Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia

Jennifer St. Sauver, Debra J. Jacobson, Michaela E. Mcgree, Michael M. Lieber, Steven J. Jacobsen

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95% confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95% CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95% CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95% CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.

Original languageEnglish (US)
Pages (from-to)760-768
Number of pages9
JournalAmerican Journal of Epidemiology
Volume164
Issue number8
DOIs
StatePublished - Oct 2006

Fingerprint

Prostatic Hyperplasia
Anti-Inflammatory Agents
Prostate-Specific Antigen
Pharmaceutical Preparations
Confidence Intervals
House Calls
Drug Users
Prostate
Ultrasonography
Cohort Studies
Age Groups
Serum
Population

Keywords

  • Anti-inflammatory agents
  • Cohort studies
  • Data collection
  • Men
  • Non-steroidal
  • Prostate-specific antigen
  • Prostatic hyperplasia
  • Questionnaires

ASJC Scopus subject areas

  • Epidemiology

Cite this

Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. / St. Sauver, Jennifer; Jacobson, Debra J.; Mcgree, Michaela E.; Lieber, Michael M.; Jacobsen, Steven J.

In: American Journal of Epidemiology, Vol. 164, No. 8, 10.2006, p. 760-768.

Research output: Contribution to journalArticle

St. Sauver, Jennifer ; Jacobson, Debra J. ; Mcgree, Michaela E. ; Lieber, Michael M. ; Jacobsen, Steven J. / Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia. In: American Journal of Epidemiology. 2006 ; Vol. 164, No. 8. pp. 760-768.
@article{7cdc2d9df8e3478e88514a67bbf5f91f,
title = "Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia",
abstract = "In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95{\%} confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95{\%} CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95{\%} CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95{\%} CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.",
keywords = "Anti-inflammatory agents, Cohort studies, Data collection, Men, Non-steroidal, Prostate-specific antigen, Prostatic hyperplasia, Questionnaires",
author = "{St. Sauver}, Jennifer and Jacobson, {Debra J.} and Mcgree, {Michaela E.} and Lieber, {Michael M.} and Jacobsen, {Steven J.}",
year = "2006",
month = "10",
doi = "10.1093/aje/kwj258",
language = "English (US)",
volume = "164",
pages = "760--768",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "8",

}

TY - JOUR

T1 - Protective association between nonsteroidal antiinflammatory drug use and measures of benign prostatic hyperplasia

AU - St. Sauver, Jennifer

AU - Jacobson, Debra J.

AU - Mcgree, Michaela E.

AU - Lieber, Michael M.

AU - Jacobsen, Steven J.

PY - 2006/10

Y1 - 2006/10

N2 - In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95% confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95% CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95% CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95% CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.

AB - In 1990-2002, the authors conducted a population-based cohort study of 2,447 Caucasian men in Olmsted County, Minnesota, to determine whether daily users of nonsteroidal antiinflammatory drugs (NSAIDs) were at lower risk than nondaily NSAID users of developing benign prostatic hyperplasia. Participants completed validated questionnaires during a home visit, including information about daily NSAID use. A random subset of 634 men also participated in a clinical evaluation including transrectal ultrasonography and assessment of serum prostate-specific antigen levels. Examinations and questionnaires were repeated biennially through 2002. Benign prostatic hyperplasia measures included development of moderate/severe urinary symptoms (American Urological Association Symptom Index score >7), low maximum urinary flow rate (<12 ml/second), prostate volume >30 ml, or prostate-specific antigen level >1.4 ng/ml. After adjustment for age, daily NSAID use was inversely associated with onset of moderate/severe urinary symptoms (hazard ratio (HR) = 0.73, 95% confidence interval (CI): 0.64, 0.82), low maximum flow rate (HR = 0.51, 95% CI: 0.43, 0.61), increased prostate volume (HR = 0.53, 95% CI: 0.41, 0.68), and elevated prostate-specific antigen level (HR = 0.52, 95% CI: 0.40, 0.68). In age-specific analyses, inverse associations between NSAID use and urinary measures tended to be stronger in the oldest age groups, although this interaction was statistically significant for only obstructive symptoms and treatment. Results suggest that NSAID use may prevent or delay development of benign prostatic hyperplasia.

KW - Anti-inflammatory agents

KW - Cohort studies

KW - Data collection

KW - Men

KW - Non-steroidal

KW - Prostate-specific antigen

KW - Prostatic hyperplasia

KW - Questionnaires

UR - http://www.scopus.com/inward/record.url?scp=33749460341&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749460341&partnerID=8YFLogxK

U2 - 10.1093/aje/kwj258

DO - 10.1093/aje/kwj258

M3 - Article

C2 - 16905643

AN - SCOPUS:33749460341

VL - 164

SP - 760

EP - 768

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 8

ER -